Top broker slaps $50 share price target on Sirtex Medical Limited

Credit: Sirtex Medical

The share price of cancer treatment specialist Sirtex Medical Limited (ASX: SRX) continues to soar as a range of credible brokers raise their valuations for the business. The stock is up 52 per cent over the past year and 260 per cent over the past three years.

If Sirtex shares edge a little higher it will almost certainly join the S&P/ASX 100 Index (ASX: XTO) of leading companies, joining other healthcare legends like CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH).

Sirtex sells doses of a specialist radiotherapy known as SIR-spheres to primarily treat advanced stage liver cancer in patients.

It also has several clinical trials in progress aimed at providing the clinical evidence to promote greater sales of the radiotherapy for a wider range of cancers and at earlier stages of those cancers onset.

If the company is successful in persuading the global community of oncologists of the merits of its treatments for a wider range of patients then dose sales could continue growing at a big rate long into the future.

At its recent AGM, the chief executive Gilman Wong forecast dose sales growth of at least 19.7 per cent in the year ahead.

This week investment bank UBS Warburg reacted by slapping a 12-month DCF price target of $50 on the business. UBS suggesting that Sirtex’s SARAH, FOXFIRE & FOXFIRE Global trials have the potential to expand its addressable market by 10x over the next five years.

UBS’s base case target is assuming 20 per cent sales growth, although it also has a bull case price target of $63.15, assuming a 25 per cent sales growth rate if Sirtex can crank dose sales faster than expected.

Other credible brokers like Macquarie Group Ltd (ASX: MQG) have a $42 price target on the stock, while US investment bank Goldman Sachs has a $40 share price target. Today the shares sell for $39.40 and remain a high-risk growth opportunity for investors looking to gain exposure to the healthcare sector and overseas earnings.

Here Are 2 Top ASX Shares Warren Buffett Would Love for BIG growth prospects...

Hot off the presses! The Motley Fool has just published a brand-new investment report and your copy is FREE. Click here to discover Warren Buffett's investing secrets and two top ASX shares Buffett could love! Your copy is free when you click here.

Motley Fool contributor Tom Richardson owns shares of Sirtex Medical Limited. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.